AbbVie, Genmab report positive Phase 3 combo trial of Epkinly after monotherapy setback
A Phase 3 combination trial of AbbVie and Genmab’s Epkinly showed positive results, restoring confidence after a recent second‑line monotherapy failure in diffuse large B‑cell lymphoma.